Physician profile
Tricia Shimer
NPI 1205820404
$2,321.83
in general payments reported to CMS, 2019-2025
30 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $370 · 2021: $245 · 2022: $414 · 2023: $384 · 2024: $349 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.26 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $336.13 | 2023-2025 | Myfembree |
| Abbvie INC. | $298.41 | 2019-2023 | Lo Loestrin Fe |
| Millicent US INC | $220.57 | 2020-2025 | Intrarosa, Femlyv, Femring |
| Myovant Sciences INC. | $195.67 | 2021-2022 | |
| Coopersurgical, INC. | $138.26 | 2020-2024 | Wallach Cryosurgical Equipment |
| Ascend Therapeutics US, LLC | $135.82 | 2019-2020 | |
| Exeltis, USA INC. | $129.86 | 2019-2025 | Slynd |
| Therapeuticsmd, INC. | $129.58 | 2019-2022 | |
| Prytime Medical Devices, INC. | $103.81 | 2023 | Er-Reboa Plus |
| Pfizer INC. | $96.41 | 2019-2024 | |
| Galderma Laboratories, L.P. | $68.89 | 2022-2024 | Dysport |
| Mayne Pharma Commercial LLC | $60.05 | 2021-2023 | |
| Avion Pharmaceuticals | $54.83 | 2019-2021 | |
| Minerva Surgical, INC | $43.77 | 2020-2022 | |
| Vertical Pharmaceuticals, LLC | $40.02 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $31.15 | 2020 | |
| Aspira Women'S Health INC | $29.67 | 2022-2023 | Ova1 |
| Bayer Healthcare Pharmaceuticals INC. | $28.36 | 2021 | |
| Astellas Pharma US INC | $22.61 | 2023 | Veozah |
| Abbott Laboratories | $21.07 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $20.85 | 2022 | |
| Molnlycke Health Care US, LLC | $19.80 | 2022 | |
| Axonics, INC. | $17.85 | 2021 | |
| Azurity Pharmaceuticals, INC. | $17.65 | 2023 | Adthyza |
| Amag Pharmaceuticals, INC. | $13.35 | 2020 | |
| Duchesnay USA Incorporated | $13.00 | 2019 | |
| Organon LLC | $11.81 | 2022 | |
| Dysis Medical, INC. | $11.29 | 2021 | |
| Acelrx Pharmaceuticals, INC. | $11.29 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tricia Shimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.